clinical trial · NCT03997383
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Transthyretin Amyloidosis (ATTR) With CardiomyopathyPlaceboPatisiran
brief summary
The purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.
started
Sep 4, 2019
primary completion
Jun 20, 2022
completion
Dec 24, 2025
last updated
Apr 20, 2026
official title
APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol